<DOC>
	<DOCNO>NCT02291783</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics pharmacodynamics young elderly healthy volunteer HTL9936 , selective M1 receptor agonist intend treatment cognitive disorder .</brief_summary>
	<brief_title>Phase I , Healthy Subject , Safety , Tolerability Pharmacokinetic Study M1 Agonist Treat Cognitive Impairment</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Body mass index ≥19 ≤ 30kg/m² Healthy subject free clinically significant illness disease Female subject must ≥65 year Subject predict CYP2D6 poor ultra rapid metabolizer History hypersensitivity study drug History epilepsy seizure Subject previous history suicidal behavior Subjects significant hearing impairment Subjects abnormal EEG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>